BridgeBio Pharma
BBIO
BBIO
129 hedge funds and large institutions have $4.39B invested in BridgeBio Pharma in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 36 increasing their positions, 48 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
11% more funds holding
Funds holding: 116 → 129 (+13)
0.34% less ownership
Funds ownership: 96.65% → 96.31% (-0.34%)
25% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 48
Holders
129
Holding in Top 10
9
Calls
$2.89M
Puts
$1.83M
Top Buyers
| 1 | +$21.1M | |
| 2 | +$19.1M | |
| 3 | +$16.9M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$16M |
| 5 |
JP Morgan Chase
New York
|
+$10.3M |
Top Sellers
| 1 | -$31.2M | |
| 2 | -$19.7M | |
| 3 | -$12.2M | |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$11.9M |
| 5 |
AG
Artal Group
Luxembourg
|
-$7.5M |